MACROGENICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
MACROGENICS, INC. (MGNX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$39.81 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-07-31.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-07-31
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$58.33M, a 252.63% decline year-over-year.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $18.51M.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $18.32M, a 84.84% decline year-over-year.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$36.85M.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $8.40M, a 93.42% decline from fiscal 2017.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $127.63M.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$112.07M, a 390.49% decline from fiscal 2015.
- MACROGENICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $38.58M, a 6.15% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-06-30 | -$58.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$39.81M 10-Q · filed 2019-07-31 | -$21.49M derived: sum of 3 quarters · filed 2019-07-31 | -$58.34M derived: sum of 4 quarters · filed 2019-07-31 | |||
| 2019-03-31 | $18.51M 10-Q · filed 2019-05-01 | $36.83M derived: sum of 2 quarters · filed 2019-05-01 | -$20.00K derived: sum of 3 quarters · filed 2019-05-01 | $38.19M derived: sum of 4 quarters · filed 2019-07-31 | |||
| 2018-12-31 | $18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$18.53M derived: sum of 2 quarters · filed 2019-02-26 | $19.68M derived: sum of 3 quarters · filed 2019-07-31 | $8.40M 10-K · filed 2019-02-26 | |||
| 2018-09-30 | -$36.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.36M derived: sum of 2 quarters · filed 2019-07-31 | -$9.92M 10-Q · filed 2018-11-07 | $110.92M derived: sum of 4 quarters · filed 2019-07-31 | |||
| 2018-06-30 | $38.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $26.93M 10-Q · filed 2019-07-31 | $147.78M derived: sum of 3 quarters · filed 2019-07-31 | $122.03M derived: sum of 4 quarters · filed 2019-07-31 | |||
| 2018-03-31 | -$11.28M 10-Q · filed 2019-05-01 | $109.56M derived: sum of 2 quarters · filed 2019-05-01 | $83.82M derived: sum of 3 quarters · filed 2019-05-01 | $159.93M derived: sum of 4 quarters · filed 2019-05-01 | |||
| 2017-12-31 | $120.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $95.10M derived: sum of 2 quarters · filed 2019-02-26 | $171.21M derived: sum of 3 quarters · filed 2019-02-26 | $127.63M 10-K · filed 2019-02-26 | |||
| 2017-09-30 | -$25.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $50.37M derived: sum of 2 quarters · filed 2018-11-07 | $6.79M 10-Q · filed 2018-11-07 | -$19.02M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $76.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $32.53M 10-Q · filed 2018-08-07 | $6.73M derived: sum of 3 quarters · filed 2019-02-26 | $54.36M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | -$43.58M 10-Q · filed 2018-05-07 | -$69.38M derived: sum of 2 quarters · filed 2019-02-26 | -$21.75M derived: sum of 3 quarters · filed 2019-02-26 | -$111.43M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | -$25.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $21.83M derived: sum of 2 quarters · filed 2019-02-26 | -$67.85M derived: sum of 3 quarters · filed 2019-02-26 | -$112.07M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $47.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$42.05M derived: sum of 2 quarters · filed 2017-11-08 | -$86.27M 10-Q · filed 2017-11-08 | -$255.87M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | -$89.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$133.91M 10-Q · filed 2017-08-02 | -$303.50M derived: sum of 3 quarters · filed 2018-02-27 | -$172.76M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$44.22M 10-Q · filed 2017-05-03 | -$213.81M derived: sum of 2 quarters · filed 2018-02-27 | -$83.08M derived: sum of 3 quarters · filed 2018-02-27 | -$111.18M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$169.59M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$38.85M derived: sum of 2 quarters · filed 2018-02-27 | -$66.96M derived: sum of 3 quarters · filed 2018-02-27 | $38.58M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $130.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $102.63M derived: sum of 2 quarters · filed 2016-11-02 | $208.18M 10-Q · filed 2016-11-02 | $186.58M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | -$28.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $77.44M 10-Q · filed 2016-08-03 | $55.84M derived: sum of 3 quarters · filed 2017-02-28 | $41.01M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $105.54M 10-Q · filed 2016-05-04 | $83.94M derived: sum of 2 quarters · filed 2017-02-28 | $69.12M derived: sum of 3 quarters · filed 2017-02-28 | $64.41M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | -$21.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$36.42M derived: sum of 2 quarters · filed 2017-02-28 | -$41.13M derived: sum of 3 quarters · filed 2017-02-28 | $41.11M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | -$14.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$19.53M derived: sum of 2 quarters · filed 2015-11-04 | $62.71M 10-Q · filed 2015-11-04 | $145.62M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$4.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $77.53M 10-Q · filed 2015-08-05 | $160.44M derived: sum of 3 quarters · filed 2016-02-29 | $160.23M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $82.24M 10-Q · filed 2015-05-06 | $82.24M 10-Q · filed 2014-05-06 | $165.15M derived: sum of 2 quarters · filed 2016-02-29 | $164.94M derived: sum of 3 quarters · filed 2016-02-29 | $155.20M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $82.91M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $82.70M derived: sum of 2 quarters · filed 2016-02-29 | $72.96M derived: sum of 3 quarters · filed 2016-02-29 | $68.74M 10-K · filed 2016-02-29 | $68.74M 10-K · filed 2014-03-20 | ||
| 2013-09-30 | -$212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$9.96M derived: sum of 2 quarters · filed 2014-11-12 | -$14.17M 10-Q · filed 2014-11-12 | -$14.17M 10-Q · filed 2013-11-12 | $3.12M derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | -$9.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$13.96M 10-Q · filed 2014-08-05 | $3.33M derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2013-03-31 | -$4.22M 10-Q · filed 2014-05-06 | $13.08M derived: sum of 2 quarters · filed 2015-03-03 | |||||
| 2012-12-31 | $17.29M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$7.47M 10-K · filed 2015-03-03 | -$7.48M 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | -$24.77M 10-Q · filed 2013-11-12 | ||||||
| 2011-12-31 | $18.34M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |